Obesity
Obesity · CVRM · 10 drugs · 3 indications
Chronic disease of excess body fat. BMI ≥30 or ≥27 with comorbidities.
Competitive Landscape (10 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Orforglipron | LLY | Oral GLP-1 agonist | Small molecule | ORAL | FILED |
| elecoglipron | AZN | Oral GLP-1 agonist | Small molecule | ORAL | PHASE3 |
| Retatrutide | LLY | GLP-1/GIP/Glucagon triple agonist | Peptide | SC | PHASE3 |
| MariTide | AMGN | GLP-1 agonist / GIP antagonist (bispecific) | Antibody-peptide conjugate | SC | PHASE3 |
| Aleniglipron | GPCR | Oral GLP-1 receptor agonist | Small molecule | ORAL | PHASE2 |
| CT-388 | ROG.SW | — | GLP-1/GIP dual agonist | SC | PHASE2 |
| ACCG-2671 | GPCR | Dual amylin/calcitonin receptor agonist | Small molecule | ORAL | PHASE1 |
| ANPA-0073 | GPCR | Apelin receptor agonist | Small molecule | ORAL | PHASE1 |
| ACCG-3535 | GPCR | Dual amylin/calcitonin receptor agonist | Small molecule | ORAL | PRECLINICAL |
| Zepbound | LLY | GLP-1/GIP dual agonist | Peptide | SC | APPROVED |
Indications (3)
Muscle-sparing weight loss
Type 2 Diabetes with Obesity
Upcoming Catalysts
Aleniglipron - Obesity - FDA Type B EoP2 MeetingREGULATORY
GPCRH1 2026
MariTide - Obesity - Ph2 Part 2 - Maintenance/Quarterly Dosing DataCLINICAL
AMGNH1 2026
Tirzepatide - MASH - Ph3 - Topline (SYNERGY-NASH)CLINICAL
LLY2026
Retatrutide - Obesity/CVD - Ph3 - Topline (TRIUMPH-3)CLINICAL
LLYFebruary 2026
Orforglipron - Obesity - FDA ApprovalREGULATORY
LLYMarch 2026
Retatrutide - Obesity - Ph3 - Topline (TRIUMPH-1)CLINICAL
LLYApril 2026
Retatrutide - T2D - Ph3 - Topline (TRIUMPH-2)CLINICAL
LLYMay 2026
Aleniglipron - Obesity - Ph3 - StartCLINICAL
GPCRMid-2026
Aleniglipron - ACCESS Full Data - Medical MeetingCLINICAL
GPCR2026
ANPA-0073 - Muscle-Sparing Weight Loss - Ph2 DecisionCLINICAL
GPCR2026
Data from Supabase · Updated 2026-03-24